about
Aberrant activation of the hedgehog signaling pathway in malignant hematological neoplasmsLoss of PRDM1/BLIMP-1 function contributes to poor prognosis of activated B-cell-like diffuse large B-cell lymphoma.Clinicopathologic, Immunophenotypic, Cytogenetic, and Molecular Features of γδ T-Cell Large Granular Lymphocytic Leukemia: An Analysis of 14 Patients Suggests Biologic Differences With αβ T-Cell Large Granular Lymphocytic Leukemia. [corrected].Prevalence and clinical implications of epstein-barr virus infection in de novo diffuse large B-cell lymphoma in Western countries.Checkpoint inhibitors in hematological malignanciesClinical implications of phosphorylated STAT3 expression in De Novo diffuse large B-cell lymphomaEBV-positive diffuse large B-cell lymphoma of the elderlyEBV-driven B-cell lymphoproliferative disorders: from biology, classification and differential diagnosis to clinical management.Age cutoff for Epstein-Barr virus-positive diffuse large B-cell lymphoma--is it necessary?Prognostic impact of c-Rel nuclear expression and REL amplification and crosstalk between c-Rel and the p53 pathway in diffuse large B-cell lymphoma.NF-κB p50 activation associated with immune dysregulation confers poorer survival for diffuse large B-cell lymphoma patients with wild-type p53.Targeting the programmed death-1 pathway in lymphoid neoplasms.Evaluation of NF-κB subunit expression and signaling pathway activation demonstrates that p52 expression confers better outcome in germinal center B-cell-like diffuse large B-cell lymphoma in association with CD30 and BCL2 functions.Prevalence and clinical implications of cyclin D1 expression in diffuse large B-cell lymphoma (DLBCL) treated with immunochemotherapy: a report from the International DLBCL Rituximab-CHOP Consortium Program.Detection of an Abnormal Myeloid Clone by Flow Cytometry in Familial Platelet Disorder With Propensity to Myeloid Malignancy.Age cutoff in lymphoma diagnosis.Lymphoma with features intermediate between aggressive T-large granular lymphocytic leukemia and hepatosplenic T-cell lymphoma: a diagnostic dilemma?Characterization of TP53 mutations in clonal cytopenia of undetermined significance.Characterization of TP53 mutations in low-grade myelodysplastic syndromes and myelodysplastic syndromes with a non-complex karyotype.Myelodysplastic Syndrome, Unclassifiable (MDS-U) With 1% Blasts Is a Distinct Subgroup of MDS-U With a Poor Prognosis.Mixed phenotype acute leukemia contains heterogeneous genetic mutations by next-generation sequencing.Myeloproliferative Neoplasms With Calreticulin Mutations Exhibit Distinctive Morphologic Features.Long-term outcomes and mutation profiling of patients with mantle cell lymphoma (MCL) who discontinued ibrutinibTransient/reversible ring sideroblasts in bone marrow of patients post cytotoxic therapies for primary malignanciesHigh p53 protein expression in therapy-related myeloid neoplasms is associated with adverse karyotype and poor outcomeSingle-Cell Quantitative PCR: Advances and Potential in Cancer DiagnosticsLeukemic phase of ALK(+) anaplastic large-cell lymphoma, small-cell variant: clinicopathologic pitfalls of a rare entityIntegrated stress response and immune cell infiltration in an ibrutinib-refractory mantle cell lymphoma patient following ONC201 treatmentClinical, immunophenotypic, and genomic findings of acute undifferentiated leukemia and comparison to acute myeloid leukemia with minimal differentiation: a study from the bone marrow pathology groupComparison of therapy-related myelodysplastic syndrome with ring sideroblasts and de novo myelodysplastic syndrome with ring sideroblastsUltra-Rapid Reporting of GENomic Targets (URGENTseq): Clinical Next-Generation Sequencing Results within 48 Hours of Sample CollectionChronic lymphocytic leukemia with proliferation centers in bone marrow is associated with younger age at initial presentation, complex karyotype, and TP53 disruptionClinico-pathologic characteristics and outcomes of the World Health Organization (WHO) provisional entity de novo acute myeloid leukemia with mutated RUNX1Efficacy of venetoclax in high risk relapsed mantle cell lymphoma (MCL) - outcomes and mutation profile from venetoclax resistant MCL patientsGenomic and clinical characterization of B/T mixed phenotype acute leukemia reveals recurrent features and T-ALL like mutationsHigh-grade B-cell lymphomas with TdT expression: a diagnostic and classification dilemmaHigh-grade B-cell lymphoma: a term re-purposed in the revised WHO classificationRAS and TP53 can predict survival in adults with T-cell lymphoblastic leukemia treated with hyper-CVADAmerican Registry of Pathology Expert Opinions: Immunohistochemical evaluation of classic Hodgkin lymphomaDeciphering the complexities of MECOM rearrangement-driven chromosomal aberrations
P50
Q26866139-5DFD8C1A-E9A5-4414-B3FB-368E08090E4DQ27853399-64D44D10-A735-49AE-8F6A-1C846B298DB7Q33426055-52B19C54-8C45-4471-93FC-9C9254EFA385Q33583294-E0DBB279-9D1C-487E-8C76-CD0D5E5B838EQ33651495-28A0D859-5792-44AF-8498-D616D8DE6FD3Q34287747-24E8B441-0381-41E7-8DE3-1FA4EA130EE8Q34343242-0A801D1B-F909-4725-81D3-F29D22BD76D6Q35040644-BE01AFA1-ED17-4479-B2A7-4329F84DA3F4Q35987244-227DEDB7-BE80-4CCB-837B-C7EB753D8D57Q36414139-28BF512F-4753-4EDA-B135-A341C5CC2515Q38915272-2FFD26FE-D9E6-4384-950F-07955111A1C8Q39153358-9677BC30-A967-4C18-971E-682ED00E6086Q40796551-664F5285-256B-41FA-9395-53A182768D58Q42230312-C87E44F2-3725-414C-9C68-22BA86E48575Q42431028-C4B59D47-CBA1-4278-A4B2-8A2C21B5FFDAQ42703285-5D993762-8F66-46FE-9870-93A9EFBE92DEQ47916739-F3CD1597-A9C3-4831-A532-9F44BB5909B9Q48156652-2D971604-8B8C-4915-91FE-6168058BCE50Q48323548-E598190A-995E-4B42-9D67-76A37A285C0BQ50017231-97644E66-63D6-474B-B49D-02FA68090F39Q52371280-9E915A9D-03C0-4700-82B4-94D350BE2BDAQ54602496-5128BC75-E9E3-48F4-9617-26E38DF22278Q57161928-AFD94202-4F4A-41D8-BA3D-503660F8ABA4Q84149492-1680F2CE-18FF-4BEB-95A6-1887968A20A1Q86030211-60A2D53A-B1FC-4BDE-BD81-4429EF4F2CEDQ87223950-F58A3BB7-385C-4A34-A388-D234C63E7B1CQ87566121-330AF5DC-0F8B-4241-BE35-EB46969EF28BQ88611119-03B841D3-C29B-4BAA-9C2C-710B808E3564Q89999028-4810DFD0-AEB8-4DB2-859E-7A2E9022E3B9Q90309294-38D75D52-A40C-4DE1-A0BB-9CF8F9CB823FQ90708227-1AC7E572-42DB-4A1F-85B2-E24A8AAA160CQ90817667-68A775E5-5890-4D2F-B5EF-FF40E1F2CF49Q90835894-3E551E1E-48A4-4751-AABD-EC2D6FC889F4Q90841930-38555DF9-ECB0-445F-B781-39BAC29927A1Q90995659-ADBE5AE6-8F56-4929-9E29-8F23CD0D375BQ91289390-1F3EB9CF-9A47-406E-A02E-DB41D59AA14CQ91311108-F9611C22-FBDE-42DE-887F-87433322F475Q91714241-FD3904A1-5430-43E5-9EA2-D5B20D497A20Q91893909-4B5C0854-B273-4FEB-9030-1EFC6C69338CQ92167814-6451C39C-6DE9-4E8B-B27B-9BFC1EFE76A6
P50
description
researcher ORCID ID = 0000-0002-6822-7880
@en
wetenschapper
@nl
name
Chi Young Ok
@ast
Chi Young Ok
@en
Chi Young Ok
@nl
type
label
Chi Young Ok
@ast
Chi Young Ok
@en
Chi Young Ok
@nl
prefLabel
Chi Young Ok
@ast
Chi Young Ok
@en
Chi Young Ok
@nl
P106
P31
P496
0000-0002-6822-7880